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Patients with rectal cancer are at high risk of disease recurrence despite neoadjuvant radiochemotherapy with 5-Fluorouracil (5FU), a
regimen that is now widely applied. In order to develop a regimen with increased antitumour activity, we previously established the
recommended dose of neoadjuvant CPT-11 (three times weekly 90mgm
 2) concomitant to hyperfractionated accelerated
radiotherapy (HART) followed by surgery within 1 week. Thirty-three patients (20 men) with a locally advanced adenocarcinoma of
the rectum were enrolled in this prospective phase II trial (1 cT2, 29 cT3, 3 cT4 and 21 cNþ). Median age was 60 years (range 43–
75 years). All patients received all three injections of CPT-11 and all but two patients completed radiotherapy as planned. Surgery
with total mesorectal excision (TME) was performed within 1 week (range 2–15 days). The preoperative chemoradiotherapy was
overall well tolerated, 24% of the patients experienced grade 3 diarrhoea that was easily manageable. At a median follow-up of 2
years no local recurrence occurred, however, nine patients developed distant metastases. The 2-year disease-free survival was 66%
(95% confidence interval 0.48–0.83). Neoadjuvant CPT-11 and HART allow for excellent local control; however, distant relapse
remains a concern in this patient population.
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Patients with rectal cancer are at high risk of both local and distant
relapse despite considerable improvements in the multidisciplin-
ary treatment.
Since the introduction of total mesorectal excision (TME) which
includes the resection of the entire mesorectal fascia, local
recurrences are reported in 5–17% of the patients, depending on
the experience of the centre, of the surgeon and whether
neoadjuvant treatment has been applied or not (Janjan et al,
1998; Kockerling et al, 1998; Kapiteijn et al, 2001; Glimelius et al,
2003; Bosset et al, 2005; Engel et al, 2005; Gerard et al, 2005;
Marijnen et al, 2005). This is in sharp contrast to former
conventional surgery without additional treatment options, which
were associated with local recurrence rates of up to 40% (Pahlman
and Glimelius, 1990; MacFarlane et al, 1993).
In the 1990s, postoperative adjuvant chemoradiotherapy for
stage II and III rectal cancer was established based on controlled
trials indicating a significant improvement of local control and
overall survival (Swedish Rectal Cancer Trial, 1997). Neoadjuvant
radiotherapy before surgery was proven to significantly
decrease the local recurrence rate and to increase survival using
an accelerated and hypofractionated schedule delivering 25Gy
in 5 days (5 5Gy) followed by immediate surgery (Swedish
Rectal Cancer Trial, 1997). The delivery of conventional radio-
therapy with or without chemotherapy before surgery has
repeatedly been shown to provide a significant advantage over
postoperative, adjuvant treatment in terms of improved local
control and reduced toxicity, however, it did not improve overall
survival (Pahlman and Glimelius, 1990; Camma et al, 2000; Sauer
et al, 2004). Over the past years, emphasis was put on neoadjuvant
chemoradiation followed by optimised surgery. It includes all
three modalities – surgery, radiotherapy and chemotherapy,
albeit variable in sequence and combination (Swedish Rectal
Cancer Trial, 1997; Kapiteijn et al, 2001; Bosset et al, 2005; Gerard
et al, 2005).
5-Fluorouracil (5FU) has been the only approved chemotherapy
agent for colorectal cancer and had been shown to improve
outcome in combination with radiotherapy in rectal cancer (NIH,
1990). Irinotecan (CPT-11), a new chemotherapy agent displaying
activity in metastatic colorectal cancer was approved in 1996 as a
single agent (Rothenberg et al, 1996). In combination with 5FU, it
significantly prolongs survival (Saltz et al, 2000). Our rationale of
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sintegrating an active systemic treatment early in the treatment
course of patients with advanced rectal cancer is several-fold. (1)
CPT-11 has excellent radiosensitising properties, allowing for
better tumour response (Chen et al, 1999). (2) The intact vascular
bed enables an optimal delivery of the chemotherapy to the
primary tumour and (3) the reduction of tumour size improves the
resection quality and potentially allows for better organ preserva-
tion. (4) Lastly, micrometastases should be eliminated early in the
disease course. Indeed, rectal adenocarcinoma has a high invasive
potential with up to 60% of patients presenting with systemic
metastases (mainly lung and liver), either at initial diagnosis or
during follow-up (Tepper et al, 2002).
Increased intensity of radiotherapy by hyperfractionation and
acceleration (HART) aims at counteracting rapid tumour repopu-
lation. The short treatment time immediately followed by surgery
allows for tumour resection before the development of late effects
(fibrosis) on normal tissue (Coucke, 1992; Coucke et al, 1995,
2006). In head and neck (Saunders et al, 1999) as well as in lung
cancers (Turrisi et al, 1999) HART has shown to improve local
control and outcome, and in rectal carcinoma we and others have
demonstrated its feasibility (Coucke, 1992; Coucke et al, 1995,
2006; Suwinski et al, 2006). In line with this hypothesis, the interval
between the end of radiotherapy and the surgical procedure has
been kept short. The Swedish and the Dutch rectal cancer trials
demonstrated excellent local control with a short course of
neoadjuvant radiotherapy followed by immediate surgery (Swedish
Rectal Cancer Trial, 1997; Kapiteijn et al, 2001). However, in
particular the latter 5 5Gy radiotherapy regimen is associated
with considerable local toxicity (Cedermark et al, 1995; Stockholm
trial, 1996). With our regimen of hyperfractionated radiotherapy,
we aimed at reducing local toxicity while maintaining an intensive
short-course regimen.
In a prior phase I trial, we established the neoadjuvant regimen
of 3 weekly doses of CPT-11 with concomitant HART followed by
immediate surgery (Voelter et al, 2003). The regimen demon-
strated promising activity in terms of tumour downstaging. Here,
we report the outcome of the phase II cohort of 33 patients treated
with this regimen.
PATIENTS AND METHODS
Patient selection
Patients with locally advanced rectal cancer stage cT3/4 and/or
cNþ without evidence of distant metastases were eligible for this
trial. Tumours had to be localised below 15cm from the anal verge
as measured by flexible recto- and/or colonoscopy. Normal
haematological, hepatic and renal function was required for
inclusion. Patients must not have had prior chemotherapy nor
radiotherapy and no malignant disease during the past 5 years. All
patients gave written informed consent before the start of
treatment and the protocol was approved by the local Ethics
Committee.
Treatment schedule
Three doses of CPT-11 at 90mgm
 2 were administered as a 30min
infusion on days 1, 8 and 15. Radiotherapy started on day 8, and
was delivered at 1.6Gy per fraction bid (6h interval) from Monday
through Friday for a total dose of 41.6Gy (26 fractions over 2.5
weeks). Total mesorectal excision was to be performed within 1
week after the end of the neoadjuvant treatment. Postoperative
(adjuvant) chemotherapy was planned to start within 4–6 weeks
after surgery. The adjuvant treatment consisted of four cycles of
CPT-11. As a result of the prior pelvic radiotherapy, escalating
doses of CPT-11 starting at 250, 300 and then 350mgm
 2, repeated
every 3 weeks were recommended.
Radiotherapy
Patients were irradiated with a linear accelerator using high-energy
photon beams of at least 6MV (Varian Clinac 2100 or Siemens
Primus). The dose prescription was at the intersection of the fields
(four-field technique). The homogeneity was within 5% of the dose
prescribed at the isocentre. All fields were to be treated during
each fraction. The field margins were defined according to a
‘standard field’ as described by Gunderson et al (1985). The upper
limit was the lower level of the fifth lumbar vertebrae and the
lateral margins were 1.5cm lateral to the pelvic bone on both sides.
The lower limit included the anal canal only if the tumour was
located in the low rectum (0–5cm form the anal verge). The
exclusion of the anal margin was checked by in vivo dosimetry
using thermoluminescent dosimetry (TLD). Corrections of the
lower limit were carried out if required.
Assessments and statistical considerations
Clinical tumour assessment at diagnosis included computed
tomography (CT) of the thorax, abdomen and pelvis as well as
magnetic resonance imaging (MRI) of the pelvis and/or transrectal
ultrasound of the rectum (TRUS). Tumour downstaging was
defined as difference between preoperative cT-stage and post-
operative ypT-stage using the sixth edition of the AJCC Cancer
Staging Manual. As the clinical staging of N-stage has low
specificity and sensitivity using standard staging methods (MRI,
TRUS, CT) (Kim et al, 1999), the comparison of cN- and pN-stages
remains unreliable and was therefore not performed in the
present trial.
During the preoperative period patients were followed for
toxicity once a week. Physical examination, full blood count and
serum chemistry were performed at least once a week. Toxicity was
graded according to National Cancer Institute Common Toxicity
Criteria (NCI CTC) version 2.0. Postoperative complications were
assessed and reported as 30-day postoperative complication rate.
After the end of adjuvant chemotherapy, patients were followed
clinically every 3 months for the first 2 years, then every 6 months.
Radiological evaluation including a CT scan of the chest, abdomen
and pelvis, or abdominal ultrasound and chest X-ray were
performed every 6 months for at least the first 3 years.
Colonoscopy was performed in regular intervals as recommended
by the Swiss Society of Gastroenterology.
The primary end point was local recurrence-free survival, with
overall survival, patterns of failure and toxicity as secondary
endpoints. We hypothesised that the addition of CPT-11 would
increase local control rate. A sample size of 30 was required to
detect a reduction of the local failure rate from 15 to o5% with a
power of 80% and a standard error of 0.05. All analyses were
performed in the intent-to-treat population. Survival data were
computed according to the Kaplan–Meier method (Kaplan and
Meier, 1958) from the date of inclusion until the date of disease
recurrence or death.
RESULTS
Patients and treatment delivery
Between 2000 and 2005, 33 patients (20 men and 13 women) were
enrolled. Median age was 60 years with a range of 43–75 years
(Table 1). Clinical tumour characteristics are listed in Table 2 and
were as follows: One patient with a cT2 tumour, 29 cT3, 3 cT4; 21
patients had clinical evidence of nodal involvement (cNþ). The
tumour was located between the anal verge and 15cm from the
anal verge with a median of 7cm (Table 1).
All but two patients completed chemoradiotherapy as scheduled
without dose reduction or treatment delay (Table 1). All patients
received the planned three CPT-11 infusions before surgery.
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sRadiotherapy was discontinued early in two patients due to grade 3
diarrhoea after 40 and 28.8Gy, respectively. The latter patient
received postoperatively a complement of irradiation of 20Gy
(2Gy daily, five fractions per week) to the sacral concavity and
surgical tumour bed combined with 5FU 300mgm
 2day
 1.
Preoperative chemoradiotherapy
Overall, the neoadjuvant treatment of HART and CPT-11 was well
tolerated. Severe toxicities (grade 3) are summarised in Table 3.
The majority of patients experienced diarrhoea that was severe in
24%, but usually easily controlled with loperamide and increased
fluid intake. Three patients needed temporarily intravenous
hydration. Abdominal cramping occurred in 6% of the patients
simultaneously to diarrhoea. Nausea and vomiting were rare as
well as severe radiation-related local inflammation (e.g. proctitis).
Myelosuppression was mild except in one patient who developed
short-lived grade 3 neutropenia after the third CPT-11 dose not
requiring any delay in radiotherapy or subsequent surgery.
Infections 31 occurred in three patients: fever without proven
infection and neutropenia 11 (1), Clostridium difficile induced
diarrhoea (2); however, no event of neutropenic fever was
observed.
Surgery and postoperative complications
All 33 patients underwent surgery. The median time from the end
of radiotherapy to surgery was 6 days (range 2–15) (Table 1).
Downstaging of the T-stage was achieved in 11 patients (33%)
(Table 2). Ten patients (30%) had nodal involvement at
pathological analysis (ypNþ).
Twenty-one patients (64%) had sphincter-sparing surgery and
12 (36%) needed an abdomino-perineal resection (APR). A
protective ileostomy had not been systematically applied at the
beginning of the study although strongly recommended. However,
according to an increased incidence of anastomotic leakage (AL) in
this patient population (21%) (Voelter et al, 2003), the protective
ileostomy has been introduced as standard procedure for low
anterior resection (overall, 15/21patients had an ileostomy). The
AL-rate in the present series is 6%. Overall, severe postoperative
complications occurred in 27% of the patients. This includes two
cases of AL in the 21 patients with low anterior resection (LAR),
one of whom did not have an ileostomy. Four patients (12%)
developed pelvic abscess without evidence of leakage (two with
APR, two with LAR and ileostomy). One patient experienced
postoperative pulmonary atelectasia and another patient perio-
perative sepsis with prolonged abdominal wound healing. One 71-
year old patient died 20 days after surgery due to myocardial
infarction and subsequent pneumonia with hypoxia. Another
patient needed a definitive colostomy 10 months after LAR due to
necrosis of the anastomosis without signs of infection. Of 12
patients with APR, 58% experienced prolonged perineal wound
healing. Five patients suffered from anorexia during the post-
operative period (15%).
Complete resection (R0) was achieved in 26 patients (79%). The
positive circumferential resection margin (CRM) rate was 7/33
(21%), however, no local recurrence occurred during a follow-up
of 34–72 months, but in four of these patients, disease recurred at
a distant site.
Adjuvant chemotherapy
Twenty-five patients (76%) received adjuvant chemotherapy. At
the time the study was conceived, adjuvant 5FU-based chemother-
apy was indicated for patients with a postoperative stage III,
applicable in our series to only 30% of patients. In fact, only 13
patients received adjuvant CPT-11 monotherapy, six patients
received a combination of CPT-11 and 5FU and five patients were
treated with adjuvant infusion of 5FU. No patient experienced
severe chemotherapy-related complications despite prior pelvic
irradiation. Of the eight patients who did not receive adjuvant
chemotherapy, one died, one refused and one patient had ypT1
ypN0 stage without indication for further treatment. In five
patients with perioperative complications, no adjuvant chemother-
apy was prescribed because of the postoperative delay.
Pattern of relapse
No local recurrence occurred at a median follow-up of 2 years.
Distant relapse (metastases) was observed in nine patients (27%),
including two of eight patients who did not receive adjuvant
chemotherapy and seven of 25 patients who received adjuvant
chemotherapy. The disease-free survival at 2 years was 66% (95%
confidence interval [CI] 0.48–0.83) (Figure 1). The main distant
failure sites were liver and lung (Table 4). One patient was
diagnosed with peritoneal metastases during surgery that were
resected and the patient is now disease free for 3þ years. The
overall survival is 93% (95% CI 0.84–1.0) and the nine patients
Table 1 Patient and treatment characteristics
Patients and tumour
N¼33
Male 20
Female 13
Age
Median 60 years
Range 43–75 years
Tumour location
Median 7cm
Range Anal verge – 15cm
Treatment delivery
Radiotherapy completed 31 (94%)
Chemotherapy completed 33 (100%)
Surgery 33 (100%)
Interval radiotherapy – surgery (days)
Median 6
Range 2–15
Table 2 Clinical (cT) and pathological (ypT) tumour stages
cT2 cT3 cT4
ypT1 2
ypT2 7
ypT3 1 18 2
ypT4 2 1
cN+ 21
ypN+ 10
Table 3 Toxicity grade 3, 4 during neoadjuvant radiochemotherapy
Toxicity (%)
Diarrhoea 24
Infections 9
Abdominal cramping 6
Nausea 3
Cardiovascular* 3
Proctitis 3
Bleeding 0
Neutropenia 3
*Vasovagal syncope in the context of pyelonephritis 21.
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swho developed distant metastases had a 3-year survival of 89%
(95% CI 0.79–1.0).
DISCUSSION
Local failure rates of rectal cancer patients have been substantially
reduced with the introduction of more extensive surgery and the
use of neoadjuvant chemo- and/or radiotherapy. Relapse rates as
low as 5% have been reported with TME alone in high volume
centres and with very experienced surgeons (MacFarlane et al,
1993). In the Dutch multicentre trial that was also conducted in
many community hospitals a local recurrence rate of 11.4% at 5
years with TME alone was observed (Kapiteijn et al, 2001;
Marijnen et al, 2005). This trial confirmed an additional benefit
of neoadjuvant short-term radiotherapy even in combination with
TME with a reduction of the local relapse rate to only 2.4% at 2
years and 5.8% at 5 years. Others have reported high local
recurrence rates up to 17% (Kockerling et al, 1998; Camma et al,
2000; Colorectal Cancer Collaborative Group, 2001; Glimelius et al,
2003; Bosset et al, 2005). This discrepancy can be explained by the
heterogeneity of the surgery, because TME was not yet widely
applied, and by the variable use of 5FU-based chemoradiotherapy.
The importance of chemotherapy has been recently underlined by
the results of two randomised trials. They demonstrated that 5FU
associated to radiotherapy reduced the rate of local failure, at least
in patients who had suboptimal surgery because the trials were
initiated before TME had been systematically applied (Bosset et al,
2005; Gerard et al, 2005).
5-Flurouracil has been the mainstay of combined chemora-
diotherapy in all large randomised trials (Bosset et al, 2004, 2005;
Sauer et al, 2004). But other active chemotherapeutic agents like
CPT-11 are now available and should be investigated within a
chemoradiotherapy strategy before surgery.
Here, we demonstrate that CPT-11, given concomitantly with
neoadjuvant hyperfractionated accelerated radiotherapy followed
by TME is well tolerated and resulted in excellent local control,
although median follow-up in our report is currently only 2 years.
Purposely, CPT-11 was begun 1 week before the start of
radiotherapy, aiming at radiosensitisation by administering the
first dose of chemotherapy before starting radiotherapy. Further-
more, chemotherapy needed to be completed approximately 2
weeks before the planned surgery in order to avoid occurrence of
myelosuppression in the peri- and postoperative period. Despite a
relatively short interval between the end of chemoradiotherapy and
surgery, downstaging was achieved in one third of the patients and
in almost 80% of patients the resection was complete with negative
margins (R0-resection). This compares favourably with other
neoadjuvant treatment regimens (Klautke et al, 2001; Chau et al,
2003; Rodel et al, 2003).
The major concern with the use of combined CPT-11 and
conventional pelvic radiotherapy has been the occurrence of
diarrhoea, a common side effect of both treatments. Our trial
suggests that the incidence of severe diarrhoea (24%) is compar-
able to that in standard 5FU regimens, the latter being associated
with diarrhoea in up to 23% of the patients (Table 5) (Minsky et al,
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Figure 1 Disease-free survival.
Table 4 Distant failure sites
UPN Liver Lung Lymph node Peritoneal
23 1
25 1
27 1
29 1 1 1
30 1
31 1 1
32 1
35 1
Abbreviation: UPN, unique patient number.
Table 5 Toxicity of neoadjuvant chemo/radiotherapy trials
Author Drug Diarrhea 3141 (%) Postop complic (%) AL (%)
Minsky ‘99 (Minsky et al, 1999) CPT-11 18 — —
Mehta ‘03 (Mehta et al, 2003) CPT-11, 5-FU 28 38
# 6
Mitchell ‘03 (Mitchell et al, 2003) CPT-11, 5-FU 27 — —
Dotor ‘04 (Dotor et al, 2004) CPT-11, 5-FU 14 — —
Levine ‘04 (Levine et al, 2004) CPT-11, 5-FU 3 — —
Hofheinz ‘05 (Hofheinz et al, 2005) CPT-11, CAP 50–75* 47 7
Klautke ‘05 (Klautke et al, 2005) CPT-11, 5-FU 32 14 9
Voelter ‘06 CPT-11 24 27 6
Minsky ‘93 (Minsky et al, 1993) 5-FU 17 45 18
Ro ¨del ‘00 (Rodel et al, 2000) 5-FU 23 28 18
Sauer ‘04 (Sauer et al, 2004) 5-FU 12 36 11
Bosset ‘04 (Bosset et al, 2004) +/5-FU
s 17/34** 22/23 —
Marijnen ‘02 (Marijnen et al, 2002) + 14** 48 11
SRCT ‘97 (Swedish Rectal Cancer Trial, 1997) + —4 4 1 1
Abbreviations. Postop complic, postoperative complication rate; AL, anastomotic leakage; 5-FU, 5 Fluorouracil; CPT-11, irinotecan; CAP, Capecitabine. Fields without values
correspond to no reported data.
#Excluding three patients with postoperative anaemia. *Grade 1–2. **Grade 2.
sRandomised phase III.
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s1993; Rodel et al, 2000; Bosset et al, 2004; Sauer et al, 2004). Other
trials investigating CPT-11 have shown similar results to ours
(Minsky et al, 1999; Mehta et al, 2003; Mitchell et al, 2003; Dotor
et al, 2004; Levine et al, 2004; Hofheinz et al, 2005; Klautke et al,
2005). The severity of diarrhoea is also influenced by the
irradiation technique. It has been reported that 20–35% of the
patients develop diarrhoea Xgrade 2 when treated with a
conventional radiotherapy technique using large irradiation fields
(Minsky et al, 1995; Bosset et al, 2004).
The overall incidence of postoperative complications is 27% and
is in the range of what has been observed with 5FU-based
protocols (Swedish Rectal Cancer Trial, 1997; Rodel et al, 2000;
Ngan et al, 2001; Marijnen et al, 2002; Mehta et al, 2003; Bosset
et al, 2004). Recently, the large randomised German trial on
chemoradiotherapy reported a 36% postoperative complication
rate (Table 5) (Sauer et al, 2004). The rate of anastomotic leakage
(AL) after low anterior resection and TME is usually in the range of
6–18% depending on the series and whether protective ileostomy
has been applied or not (Swedish Rectal Cancer Trial, 1997; Rodel
et al, 2000; Marijnen et al, 2002; Mehta et al, 2003; Sauer et al,
2004). The AL rate of 6% in our trial compares favourably and
indicates that the administration of neoadjuvant CPT-11 with
radiotherapy is safe.
Delayed perineal wound healing is common after APR and
neoadjuvant radiotherapy. It has been described to occur in about
1/3 of the patients (Pahlman and Glimelius, 1990; Kapiteijn et al,
2001; Marijnen et al, 2002). In the present series, the duration of
perineal wound healing was prolonged in more than half of the
patients who underwent APR. This is likely due to the use of CPT-
11. Ultimately, the wound healed in all seven patients.
Despite the use of neoadjuvant and adjuvant chemotherapy the
incidence of distant metastases has not been reduced during the
last decades. Distant failure rates of 30–40% are consistently
reported throughout all large phase II and III trials and account for
the poor outcome of patients with locally advanced rectal cancer
compared to patients with colon cancer (Sanfilippo et al, 2001;
Marijnen et al, 2003b; Sauer et al, 2004). By 5 years, approximately
one third of the patients will die of their disease mainly due to the
occurrence of distant metastases (Tepper et al, 2002; Bosset et al,
2005; Marijnen et al, 2005).
In the present trial, a total cumulative dose of neoadjuvant CPT-
11 of 270mgm
 2 was administered and three quarters of the
patients received four cycles of adjuvant chemotherapy. Never-
theless, this did not prevent a 32% incidence of distant metastases.
However, by today’s standards the patients in this trial may not
have received optimal adjuvant therapy. Recently, combination
chemotherapy with infusion of 5FU and oxaliplatin has been
shown to be superior to infusion of 5FU alone in patients with
stage II and III colon cancer (Andre et al, 2004), while the
combination of 5FU and CPT-11 failed to demonstrate a similar
benefit for the combination (Van Cutsem et al, 2005). At the time
the trial was conceived, adjuvant chemotherapy with bolus 5FU
and leucovorin was indicated only for patients with postoperative
stage III colorectal cancer, representing only 30% of the patients in
the current trial. However, at that time CPT-11 was emerging as a
promising new agent with significant activity in second- and first-
line therapy of metastatic colorectal cancer. We purposely wanted
to expose the patient to the same chemotherapy agent throughout
the first-line therapy.
Interestingly, more than half of the patients who had minimal or
involved circumferential resection margins consecutively devel-
oped distant metastases, while no local recurrence occurred. The
majority of these patients had undergone an abdomino-perineal
resection. Positive circumferential resection margin involvement is
well known to be an important risk factor for disease recurrence,
both for distant metastases and/or locally (Nagtegaal et al, 2002;
Marijnen et al, 2003a,b). This seems to be particularly frequent
after abdomino-perineal resection (Marijnen et al, 2005).
Overall, the association of positive CRM and distant failure
suggests that an aggressive biology of the disease leads to early
micrometastatic spread while efficient local treatment has
prevented local relapse. This is further reinforced by the
observation that none of the nine patients who developed distant
metastases in this series had a local recurrence at 3 years of follow-
up.
These results stress the importance of delivering potent systemic
agents early in the treatment course in order to diminish the
incidence of distant metastases and to improve the outcome of
patients with locally advanced rectal cancer. Future trials should
aim at developing regimens with more active chemotherapy
including novel targeted agents. In parallel, radiotherapy techni-
ques have to be adapted in order to spare a maximum of
surrounding healthy tissue. Intensity modulated radiation therapy
is one of these new techniques. For a more conformal approach, a
better definition of target volume is a prerequisite. Therefore, MRI
and PET-CT have to be evaluated for their role in determining
tumour target volumes with high accuracy.
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